TargetMol

BMY-27709

Product Code:
 
TAR-T26873
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T26873-1mg1mg£352.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26873-5mg5mg£736.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26873-10mg10mg£978.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26873-25mg25mg£1,348.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26873-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26873-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26873-500mg500mg£4,006.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
BMY-27709 is an inhibitor of influenza virus growth with an IC50 of 3-8 microM for A/WSN/33 virus growth and is also active against all H1 and H2 subtype viruses tested. BMY-27709 acted against H1 and H2 viruses early in infection, suggesting that the target for inhibition is the hemagglutinin protein. However, BMY-27709 was found to be inactive against H3 subtype viruses, as well as influenza B/Lee/40 virus.
CAS:
99390-76-8
Formula:
C17H24ClN3O2
Molecular Weight:
337.85
Pathway:
Microbiology/Virology
Purity:
0.98
SMILES:
C[C@@H]1CCC[C@@H]2C[C@H](CCN12)NC(=O)c1cc(Cl)c(N)cc1O
Target:
Influenza Virus

References

1. Hsieh HP, Hsu JT. Strategies of development of antiviral agents directed against influenza virus replication. Curr Pharm Des. 2007;13(34):3531-42. Review. PubMed PMID: 18220789. 2. Yu KL, Torri AF, Luo G, Cianci C, Grant-Young K, Danetz S, Tiley L, Krystal M, Meanwell NA. Structure-activity relationships for a series of thiobenzamide influenza fusion inhibitors derived from 1,3,3-trimethyl-5-hydroxy-cyclohexylmethylamine. Bioorg Med Chem Lett. 2002 Dec 2;12(23):3379-82. PubMed PMID: 12419365. 3. Deshpande MS, Wei J, Luo G, Cianci C, Danetz S, Torri A, Tiley L, Krystal M, Yu KL, Huang S, Gao Q, Meanwell NA. An approach to the identification of potent inhibitors of influenza virus fusion using parallel synthesis methodology. Bioorg Med Chem Lett. 2001 Sep 3;11(17):2393-6. PubMed PMID: 11527739. 4. Combrink KD, Gulgeze HB, Yu KL, Pearce BC, Trehan AK, Wei J, Deshpande M, Krystal M, Torri A, Luo G, Cianci C, Danetz S, Tiley L, Meanwell NA. Salicylamide inhibitors of influenza virus fusion. Bioorg Med Chem Lett. 2000 Aug 7;10(15):1649-52. PubMed PMID: 10937716.